Stock ELUT ELUTIA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Elutia Inc.

Equities

ELUT

US05479K1060

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-06-04 pm EDT 		5-day change 1st Jan Change
3.35 USD -0.00% Intraday chart for Elutia Inc. +1.51% +55.09%
May. 09 Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
AQ
Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Elutia : Q1 2024 Financial Results Presentation
PU
Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M
MT
Transcript : Elutia Inc., Q1 2024 Earnings Call, May 09, 2024
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
AQ
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
AQ
Elutia Planet MicroCap Showcase: VEGAS 2024 Presentation
PU
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
AQ
Transcript : Elutia Inc., Q4 2023 Earnings Call, Mar 07, 2024
Elutia Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Elutia Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (ELUT) ELUTIA Posts Q4 Revenue $5.9M, vs. Street Est of $6.6M
MT
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
AQ
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
AQ
Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants
AQ
Transcript : Elutia Inc. - Special Call
Elutia Regains Compliance with Nasdaq Listing Requirements
AQ
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance
AQ
Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELUT Stock
  4. News Elutia Inc.